Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|February 1, 1999
- Psychiatric Times Vol 16 No 2
- Volume 16
- Issue 2
Woman With a Finger Stuck in Her Nose
Woman With a Finger Stuck in Her Nose - Poetry of the Times
Advertisement
What was funny
wasn't where it was stuck,
or her phoning
Please, a surgeon,
my brain is leaking out!
No, the funny part was
the hospital operator
triaging her right
to psychiatry.
It's comical, too
when you get your own
finger stuck somewhere
and your brain starts to ooze,
how someone lands
from out of the blue
with a cork,
some suture,
or a few words
that hold you together
like crazy glue,
solid as a kiss,
a joke,
a prayer.
© CME LLC
2/99
Read more
of Dr. Berlin's work.
Articles in this issue
over 27 years ago
Chavez Warns of Declining Mental Health Resourcesover 27 years ago
Commentary: Kevorkian on Trialover 27 years ago
The Politics of Health Care Can the APA Make a Difference?over 27 years ago
National Center for Alternative Medicine Establishedover 27 years ago
Scientific Assessment of Alternative Medicineover 27 years ago
Biofeedback and Anxietyover 27 years ago
Music Therapy for Inpatient Psychiatric Care in the 1990sover 27 years ago
Culture and Eating Disordersover 27 years ago
Therapeutic Aspects of the Human-Companion Animal InteractionAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5